Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Last updated: October 20, 2025
Sponsor: Alexza Pharmaceuticals, Inc.
Overall Status: Suspended

Phase

N/A

Condition

Tourette's Syndrome

Manic Disorders

Mood Disorders

Treatment

Loxapine 10 MG

Clinical Study ID

NCT03513549
TV571-CNS-40036
  • Ages > 18
  • All Genders

Study Summary

This postmarketing observational study will evaluate the safety of ADASUVE® in treating patients with agitation associated with schizophrenia or bipolar I disorder.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients may be included in the study if they meet all of the following criteria:

  1. The patient is a man or woman who is 18 years of age or older at time of enrollment.

  2. The patient is receiving ADASUVE for agitation in a medical or psychiatric emergencysetting or in a psychiatric inpatient setting. (Note: Patients with a prior historyof treatment with ADASUVE may also be included in the study.)

  3. The patient (or caregiver or legally authorized representative) is willing and ableto provide written informed consent (and assent, where applicable) afteradministration of ADASUVE treatment.

Exclusion

Exclusion Criteria:

There are no exclusion criteria for this study.

Study Design

Total Participants: 10000
Treatment Group(s): 1
Primary Treatment: Loxapine 10 MG
Phase:
Study Start date:
November 04, 2014
Estimated Completion Date:
September 30, 2027

Study Description

This is a multicenter, prospective, observational study conducted to evaluate the safety of ADASUVE treatment when used in real-world clinical setting in patients with agitation associated with schizophrenia or bipolar I disorder.

The primary objective of the study is to assess the safety of ADASUVE treatment in real-world clinical settings.

The secondary objective of the study is to describe the characteristics of patients, including demographic and baseline characteristics, after administration of ADASUVE treatment in real-world clinical settings.

The study population will consist of a non-randomized cohort of approximately 10000 adult men and women who have agitation associated with schizophrenia or bipolar I disorder (naïve and non-naïve to ADASUVE treatment).

Connect with a study center

  • Pharmaceutical Research Associates, Inc

    Raleigh, North Carolina 27612
    United States

    Site Not Available

  • Pharmaceutical Research Associates, Inc

    Raleigh 4487042, North Carolina 4482348 27612
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.